Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
MWN-AI** Summary
As of February 19, 2026, Innate Pharma SA, a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer, reported the total number of its outstanding shares and associated voting rights in compliance with French regulatory requirements. The company has a total of **93,743,243 ordinary shares** outstanding, complemented by **6,140 Preferred Shares 2016** and **7,581 Preferred Shares 2017**.
The total number of theoretical voting rights, which includes all shares eligible for voting, is calculated at **94,484,443**. This total includes shares tied to the AGAP 2016 agreement, which provides seemingly enhanced voting rights: **130** for the AGAP 2016-1 and **111** for the AGAP 2016-2. In stark contrast, there are no voting rights associated with the AGAP 2017.
When considering the exercisable voting rights, which account for shares not held in treasury or with suspended rights, the total drops slightly to **94,465,868**. This distinction is crucial for accurate reporting and regulatory transparency, ensuring that the market remains properly informed.
Innate Pharma, headquartered in Marseille, France, is publicly traded on both Euronext Paris and the Nasdaq under the ticker symbols IPH and IPHA, respectively. The company's focus remains on developing next-generation antibody therapeutics to address critical medical needs in oncology, evidenced by its product pipeline, which includes collaborations with major biopharmaceutical firms like Sanofi and AstraZeneca.
Investors are encouraged to consult Innate Pharma's website for further details and ongoing updates, which underscore the firm’s commitment to transforming cancer treatment amid an evolving healthcare landscape.
MWN-AI** Analysis
As of February 19, 2026, Innate Pharma exhibits a compelling yet nuanced picture regarding its share structure and voting rights. The company has 93,743,243 ordinary shares and an additional 13,721 preferred shares dated 2016 and 2017, leading to a comprehensive theoretical voting rights count of 94,484,443. However, after accounting for treasury shares and suspended voting rights, the total exercisable voting rights are slightly reduced to 94,465,868.
For investors, the disparity between theoretical and exercisable voting rights signals a degree of corporate governance potential to influence decision-making within the company. The presence of over 94 million voting rights can bolster shareholder engagement, especially as Innate navigates its clinical-stage developments in immunotherapy—a sector known for volatility but also for high rewards.
When considering investment in Innate, it is crucial to weigh these factors alongside their ongoing pipeline, which includes innovative treatments like IPH4502 and collaborations with heavyweights such as AstraZeneca and Sanofi. Companies with strong academic partnerships tend to mitigate risks and enhance innovation, thus leading to potentially lucrative outcomes for shareholders.
However, potential investors should remain cognizant of the inherent risks in biotechnology investments, marked by regulatory hurdles and the possibility of clinical trial setbacks. Furthermore, as share structures can affect market sentiment, investors should keep a close eye on changes in share consolidation and voting power dynamics.
In conclusion, while Innate Pharma's strong pipeline and robust theoretical voting rights establish a foundation for optimism, prudent investors must conduct thorough diligence concerning both the macro and micro factors affecting their financial positioning.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026:
Total number of shares outstanding: | 93,743,243 ordinary shares |
6,140 Preferred Shares 2016 7,581 Preferred Shares 2017 | |
Total number of theoretical voting rights (1): Total number of exercisable voting rights (2): | 94,484,443 94,465,868 |
(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X .
Information about Innate Pharma shares
ISIN code | FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website ( http://www.amf-france.org ) or on Innate Pharma’s website ( www.innate-pharma.com ), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218425598/en/
Investors & Media Relations
Innate Pharma
Stéphanie Cornen
stephanie.cornen@innate-pharma.fr
Investor Relations
investors@innate-pharma.fr
FAQ**
How does the performance of Innate Pharma - Class A IPHYF compare to its peers in the biotechnology sector, particularly in terms of market share and pipeline development?
What are the key milestones and anticipated timelines for the clinical trials of Innate Pharma - Class A IPHYF's lead drug candidates, such as IPH4502 and lacutamab?
Given Innate Pharma - Class A IPHYF's collaborations with major companies like AstraZeneca, how do these partnerships impact the company's financial health and future growth potential?
What are the specific risks associated with investing in Innate Pharma - Class A IPHYF, as outlined in the latest Universal Registration Document filed with the AMF?
**MWN-AI FAQ is based on asking OpenAI questions about Innate Pharma - Class A (OTC: IPHYF).
NASDAQ: IPHYF
IPHYF Trading
-63.76% G/L:
$2.155 Last:
100 Volume:
$2.155 Open:
